Endometrial cancer (EC) is increasingly prevalent, particularly among women with obesity, insulin resistance, and other metabolic disorders, and progestin therapy is widely used for managing endometrial hyperplasia and abnormal uterine bleeding. However, evidence comparing the effectiveness of progestins alone versus combined therapy with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in reducing EC risk remains limited.
To address this gap, a study evaluated the risk of developing endometrial cancer among women treated with progestins alone versus combined progestins and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in women with endometrial hyperplasia or benign uterine pathology, in 444,820 women, with a mean age of 35.5 years. The study found that treatment with GLP-1RAs combined with progestins was associated with a significantly lower risk of EC compared with…
